Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. (2021)

First Author: DiNardo CD
Attributed to:  Transcriptional Regulation of GATA-1 funded by MRC


No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/S1470-2045(21)00494-0

PubMed Identifier: 34672961

Publication URI: http://europepmc.org/abstract/MED/34672961

Type: Journal Article/Review

Volume: 22

Parent Publication: The Lancet. Oncology

Issue: 11

ISSN: 1470-2045